Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Faeth Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −4 vs. Q2 2024
- Shares held
- 2.21M
- +106.8K (+5.1%) vs. Q2 2024
- Total value
- $1.32M
- +$18.3K (+1.4%) vs. Q2 2024
- New holders
- 1
- 4 more added
- Sold out
- 5
- 5 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $333.8M |
| Q1 2026 | 30 | $68.0M |
| Q4 2025 | 10 | $514.8K |
| Q3 2025 | 9 | $466.2K |
| Q2 2025 | 10 | $600.0K |
| Q1 2025 | 20 | $760.2K |
| Q4 2024 | 24 | $1.16M |
| Q3 2024 | 19 | $1.32M |
| Q2 2024 | 24 | $1.31M |
| Q1 2024 | 25 | $2.43M |
| Q4 2023 | 24 | $2.05M |
| Q3 2023 | 23 | $2.38M |
| Q2 2023 | 26 | $3.58M |
| Q1 2023 | 27 | $4.71M |
| Q4 2022 | 28 | $3.93M |
| Q3 2022 | 31 | $4.47M |
| Q2 2022 | 40 | $7.06M |
| Q1 2022 | 43 | $8.21M |
| Q4 2021 | 38 | $19.7M |
| Q3 2021 | 42 | $37.1M |
| Q2 2021 | 34 | $22.7M |
| Q1 2021 | 40 | $45.8M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Faeth Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 650,000 | $388.7K | 0.12% | 00.0% | Unchanged |
| Vanguard Group Inc | 618,757 | $370.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 215,572 | $128.9K | 0.00% | −8,213−3.7% | Reduced |
| Boothbay Fund Management, LLC | 172,835 | $103.4K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 163,139 | $97.6K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 90,428 | $54.1K | 0.00% | +90,428 | New |
| Citadel Advisors LLC | 66,044 | $39.5K | 0.00% | +50,678+329.8% | Added |
| Bridgeway Capital Management, LLC | 47,900 | $28.6K | 0.00% | −30,000−38.5% | Reduced |
| National Bank of Canada | 45,575 | $27.3K | 0.00% | +35,575+355.8% | Added |
| Northern Trust Corp | 25,983 | $15.5K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 25,774 | $15.4K | 0.00% | 00.0% | Unchanged |
| Raymond James & Associates | 20,000 | $12.0K | 0.00% | +6,000+42.9% | Added |
| Cresset Asset Management, LLC | 19,671 | $11.8K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 13,926 | $8.33K | 0.00% | −121−0.9% | Reduced |
| Morgan Stanley | 12,219 | $7.31K | 0.00% | 00.0% | Unchanged |
| Deuterium Capital Management, LLC | 11,000 | $6.58K | 0.01% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 7,029 | $4.20K | 0.00% | −58−0.8% | Reduced |
| JPMorgan Chase & Co | 707 | $422 | 0.00% | −41−5.5% | Reduced |
| Bank of America Corp | 258 | $154 | 0.00% | +119+85.6% | Added |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −18,600−100.0% | Sold out |
| Leo Wealth, LLC | 0 | $0 | 0.00% | −14,845−100.0% | Sold out |
| Banque Cantonale Vaudoise | 0 | $0 | 0.00% | −3,900−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −247−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |